Global Psychoactive Substances 麻豆原创 Research Report 2024

Publication ID:

PB503244511

Publication Date:

March 20, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Psychoactive Substances market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Psychoactive Substances is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Psychoactive Substances is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Psychoactive Substances in Cancer is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Psychoactive Substances include Zynerba Pharmaceuticals, GW Pharmaceuticals PLC., Enecta., Teewinot Life Sciences, GD Pharma, Cape Bouvard Technologies Pty Ltd, AusCann Group Holdings Pty Ltd., Cannabics Pharmaceuticals Inc. and Alpha-CAT, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Psychoactive Substances, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Psychoactive Substances.
Report Scope
The Psychoactive Substances market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Psychoactive Substances market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Psychoactive Substances companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Zynerba Pharmaceuticals
GW Pharmaceuticals PLC.
Enecta.
Teewinot Life Sciences
GD Pharma
Cape Bouvard Technologies Pty Ltd
AusCann Group Holdings Pty Ltd.
Cannabics Pharmaceuticals Inc.
Alpha-CAT
Tilray
Cyrelian Pty Ltd.
MedReleaf Australia
Segment by Type
Stimulants
Cannabinoids
Hallucinogens
Depressants
Segment by Application
Cancer
Neuropathic Disorders
Spasticity
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Psychoactive Substances companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Psychoactive Substances 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Stimulants
1.2.3 Cannabinoids
1.2.4 Hallucinogens
1.2.5 Depressants
1.3 麻豆原创 by Application
1.3.1 Global Psychoactive Substances 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Cancer
1.3.3 Neuropathic Disorders
1.3.4 Spasticity
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Psychoactive Substances 麻豆原创 Perspective (2019-2030)
2.2 Psychoactive Substances Growth Trends by Region
2.2.1 Global Psychoactive Substances 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Psychoactive Substances Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Psychoactive Substances Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Psychoactive Substances 麻豆原创 Dynamics
2.3.1 Psychoactive Substances Industry Trends
2.3.2 Psychoactive Substances 麻豆原创 Drivers
2.3.3 Psychoactive Substances 麻豆原创 Challenges
2.3.4 Psychoactive Substances 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Psychoactive Substances Players by Revenue
3.1.1 Global Top Psychoactive Substances Players by Revenue (2019-2024)
3.1.2 Global Psychoactive Substances Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Psychoactive Substances 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Psychoactive Substances Revenue
3.4 Global Psychoactive Substances 麻豆原创 Concentration Ratio
3.4.1 Global Psychoactive Substances 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Psychoactive Substances Revenue in 2023
3.5 Psychoactive Substances Key Players Head office and Area Served
3.6 Key Players Psychoactive Substances Product Solution and Service
3.7 Date of Enter into Psychoactive Substances 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Psychoactive Substances Breakdown Data by Type
4.1 Global Psychoactive Substances Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Psychoactive Substances Forecasted 麻豆原创 Size by Type (2025-2030)
5 Psychoactive Substances Breakdown Data by Application
5.1 Global Psychoactive Substances Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Psychoactive Substances Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Psychoactive Substances 麻豆原创 Size (2019-2030)
6.2 North America Psychoactive Substances 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Psychoactive Substances 麻豆原创 Size by Country (2019-2024)
6.4 North America Psychoactive Substances 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Psychoactive Substances 麻豆原创 Size (2019-2030)
7.2 Europe Psychoactive Substances 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Psychoactive Substances 麻豆原创 Size by Country (2019-2024)
7.4 Europe Psychoactive Substances 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Psychoactive Substances 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Psychoactive Substances 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Psychoactive Substances 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Psychoactive Substances 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Psychoactive Substances 麻豆原创 Size (2019-2030)
9.2 Latin America Psychoactive Substances 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Psychoactive Substances 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Psychoactive Substances 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Psychoactive Substances 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Psychoactive Substances 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Psychoactive Substances 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Psychoactive Substances 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Zynerba Pharmaceuticals
11.1.1 Zynerba Pharmaceuticals Company Detail
11.1.2 Zynerba Pharmaceuticals Business Overview
11.1.3 Zynerba Pharmaceuticals Psychoactive Substances Introduction
11.1.4 Zynerba Pharmaceuticals Revenue in Psychoactive Substances Business (2019-2024)
11.1.5 Zynerba Pharmaceuticals Recent Development
11.2 GW Pharmaceuticals PLC.
11.2.1 GW Pharmaceuticals PLC. Company Detail
11.2.2 GW Pharmaceuticals PLC. Business Overview
11.2.3 GW Pharmaceuticals PLC. Psychoactive Substances Introduction
11.2.4 GW Pharmaceuticals PLC. Revenue in Psychoactive Substances Business (2019-2024)
11.2.5 GW Pharmaceuticals PLC. Recent Development
11.3 Enecta.
11.3.1 Enecta. Company Detail
11.3.2 Enecta. Business Overview
11.3.3 Enecta. Psychoactive Substances Introduction
11.3.4 Enecta. Revenue in Psychoactive Substances Business (2019-2024)
11.3.5 Enecta. Recent Development
11.4 Teewinot Life Sciences
11.4.1 Teewinot Life Sciences Company Detail
11.4.2 Teewinot Life Sciences Business Overview
11.4.3 Teewinot Life Sciences Psychoactive Substances Introduction
11.4.4 Teewinot Life Sciences Revenue in Psychoactive Substances Business (2019-2024)
11.4.5 Teewinot Life Sciences Recent Development
11.5 GD Pharma
11.5.1 GD Pharma Company Detail
11.5.2 GD Pharma Business Overview
11.5.3 GD Pharma Psychoactive Substances Introduction
11.5.4 GD Pharma Revenue in Psychoactive Substances Business (2019-2024)
11.5.5 GD Pharma Recent Development
11.6 Cape Bouvard Technologies Pty Ltd
11.6.1 Cape Bouvard Technologies Pty Ltd Company Detail
11.6.2 Cape Bouvard Technologies Pty Ltd Business Overview
11.6.3 Cape Bouvard Technologies Pty Ltd Psychoactive Substances Introduction
11.6.4 Cape Bouvard Technologies Pty Ltd Revenue in Psychoactive Substances Business (2019-2024)
11.6.5 Cape Bouvard Technologies Pty Ltd Recent Development
11.7 AusCann Group Holdings Pty Ltd.
11.7.1 AusCann Group Holdings Pty Ltd. Company Detail
11.7.2 AusCann Group Holdings Pty Ltd. Business Overview
11.7.3 AusCann Group Holdings Pty Ltd. Psychoactive Substances Introduction
11.7.4 AusCann Group Holdings Pty Ltd. Revenue in Psychoactive Substances Business (2019-2024)
11.7.5 AusCann Group Holdings Pty Ltd. Recent Development
11.8 Cannabics Pharmaceuticals Inc.
11.8.1 Cannabics Pharmaceuticals Inc. Company Detail
11.8.2 Cannabics Pharmaceuticals Inc. Business Overview
11.8.3 Cannabics Pharmaceuticals Inc. Psychoactive Substances Introduction
11.8.4 Cannabics Pharmaceuticals Inc. Revenue in Psychoactive Substances Business (2019-2024)
11.8.5 Cannabics Pharmaceuticals Inc. Recent Development
11.9 Alpha-CAT
11.9.1 Alpha-CAT Company Detail
11.9.2 Alpha-CAT Business Overview
11.9.3 Alpha-CAT Psychoactive Substances Introduction
11.9.4 Alpha-CAT Revenue in Psychoactive Substances Business (2019-2024)
11.9.5 Alpha-CAT Recent Development
11.10 Tilray
11.10.1 Tilray Company Detail
11.10.2 Tilray Business Overview
11.10.3 Tilray Psychoactive Substances Introduction
11.10.4 Tilray Revenue in Psychoactive Substances Business (2019-2024)
11.10.5 Tilray Recent Development
11.11 Cyrelian Pty Ltd.
11.11.1 Cyrelian Pty Ltd. Company Detail
11.11.2 Cyrelian Pty Ltd. Business Overview
11.11.3 Cyrelian Pty Ltd. Psychoactive Substances Introduction
11.11.4 Cyrelian Pty Ltd. Revenue in Psychoactive Substances Business (2019-2024)
11.11.5 Cyrelian Pty Ltd. Recent Development
11.12 MedReleaf Australia
11.12.1 MedReleaf Australia Company Detail
11.12.2 MedReleaf Australia Business Overview
11.12.3 MedReleaf Australia Psychoactive Substances Introduction
11.12.4 MedReleaf Australia Revenue in Psychoactive Substances Business (2019-2024)
11.12.5 MedReleaf Australia Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Zynerba Pharmaceuticals
GW Pharmaceuticals PLC.
Enecta.
Teewinot Life Sciences
GD Pharma
Cape Bouvard Technologies Pty Ltd
AusCann Group Holdings Pty Ltd.
Cannabics Pharmaceuticals Inc.
Alpha-CAT
Tilray
Cyrelian Pty Ltd.
MedReleaf Australia

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.